{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:38:21Z","timestamp":1792028301287,"version":"4.4.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.ejca.2009.11.001","type":"journal-article","created":{"date-parts":[[2009,12,17]],"date-time":"2009-12-17T14:21:34Z","timestamp":1261059694000},"page":"439-448","source":"Crossref","is-referenced-by-count":301,"title":["VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management"],"prefix":"10.1016","volume":"46","author":[{"given":"Hassane","family":"Izzedine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Philippe","family":"Spano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Khayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2009.11.001_bib1","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1371\/journal.pmed.0050207","article-title":"The relationship between proteinuria and coronary risk: a systematic review and meta-analysis","volume":"5","author":"Perkovic","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2009.11.001_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/bmj.305.6844.29-a","article-title":"Effect of iodinated water soluble contrast media on urinary protein assays","volume":"305","author":"Morcos","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2009.11.001_bib3","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/clinchem\/34.10.2019","article-title":"Albumin excretion rate, albumin concentration, albumin\/creatinine ratio compared for screening diabetics for slight albuminuria","volume":"34","author":"Hutchison","year":"1988","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejca.2009.11.001_bib4","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1681\/ASN.V1341034","article-title":"Use of the albumin\/creatinine ratio to detect microalbuminuria: implications of sex and race","volume":"13","author":"Mattix","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejca.2009.11.001_bib5","series-title":"Pathophysiology of renal disease","author":"Rose","year":"1987"},{"key":"10.1016\/j.ejca.2009.11.001_bib6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1503\/cmaj.061590","article-title":"Urine proteomics: the present and future of measuring urinary protein components in disease","volume":"177","author":"Barratt","year":"2007","journal-title":"CMAJ"},{"key":"10.1016\/j.ejca.2009.11.001_bib7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejca.2009.11.001_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","article-title":"Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension","volume":"50","author":"Izzedine","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejca.2009.11.001_bib9","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2009.11.001_bib10","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2005.10.017","article-title":"Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer","volume":"23","author":"Hurwitz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2009.11.001_bib11","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2009.11.001_bib12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ejca.2009.11.001_bib13","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2009.11.001_bib14","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2009.11.001_bib15","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2009.11.001_bib16","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl.","key":"10.1016\/j.ejca.2009.11.001_bib17","article-title":"Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)","volume":"25","author":"Hutson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.ejca.2009.11.001_bib18","article-title":"Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium","volume":"25","author":"Sridhar","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ejca.2009.11.001_bib19","article-title":"Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial","volume":"26","author":"Tang","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ejca.2009.11.001_bib20","article-title":"Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinumand erlotinib-resistant adenocarcinoma of the lung (NSCLA)","volume":"25","author":"Massarelli","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ejca.2009.11.001_bib21","article-title":"VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study","volume":"25","author":"Tew","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2009.11.001_bib22","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0140-6736(08)60661-3","article-title":"Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study","volume":"371","author":"Spano","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2009.11.001_bib23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","article-title":"Axitinib treatment in patients with cytokinerefractory metastatic renal-cell cancer: a phase II study","volume":"8","author":"Rixe","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2009.11.001_bib24","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2009.11.001_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia- Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2009.11.001_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renalcell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2009.11.001_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clearcell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2009.11.001_bib28","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2009.11.001_bib29","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1159\/000088481","article-title":"Managing patients treated with bevacizumab combination therapy","volume":"69","author":"Gordon","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2009.11.001_bib30","unstructured":"Hochster HS, Welles L, Hart L, et al. Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): preliminary results of the randomized TREE-2 trial. In: Paper presented at the 2005 Gastrointestinal cancers symposium; January 27\u201329, Hollywood, Fla. Abstract 241, 2005."},{"issue":"Suppl.","key":"10.1016\/j.ejca.2009.11.001_bib31","article-title":"An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors","volume":"24","author":"Eskens","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2009.11.001_bib32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jnci\/djm311","article-title":"A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib","volume":"100","author":"Patel","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2009.11.001_bib33","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/ndt\/gfl565","article-title":"Thrombotic microangiopathy and anti-VEGF agents","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejca.2009.11.001_bib34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","article-title":"Renal thrombotic microangiopathy caused by anti VEGF-antibody treatment for metastatic renal-cell carcinoma","volume":"8","author":"Frangie","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2009.11.001_bib35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/ncpneph0476","article-title":"Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma","volume":"3","author":"Roncone","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.ejca.2009.11.001_bib36","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2009.11.001_bib37","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/ki.2008.256","article-title":"Glomerular disease related to anti-VEGF therapy","volume":"74","author":"Stokes","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejca.2009.11.001_bib38","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib","volume":"24","author":"Boll\u00e9e","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejca.2009.11.001_bib39","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejca.2009.11.001_bib40","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2009.11.001_bib41","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1053\/j.ajkd.2006.11.024","article-title":"Nephrotic syndrome after bevacizumab: case report and literature review","volume":"49","author":"George","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejca.2009.11.001_bib42","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1093\/ndt\/gfm199","article-title":"Interstitial nephritis in a patient taking sorafenib","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejca.2009.11.001_bib43","doi-asserted-by":"crossref","unstructured":"Billemont B, Rixe O, Meric JB, et al. Renal safety of sunitinib treatment: a prospective study for patients (pts) with metastatic renal cell carcinoma (mRCC). In: ASCO 2008, Poster E1.","DOI":"10.1200\/jco.2008.26.15_suppl.16146"},{"key":"10.1016\/j.ejca.2009.11.001_bib44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ejca.2009.11.001_bib45","article-title":"Examining ethnic differences for bevacizumab-induced hypertension and proteinuria","volume":"25","author":"Choi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2009.11.001_bib46","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMra052131","article-title":"Hereditary proteinuria syndromes and mechanisms of proteinuria","volume":"354","author":"Tryggvason","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2009.11.001_bib47","doi-asserted-by":"crossref","first-page":"14448","DOI":"10.1073\/pnas.0703577104","article-title":"Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions","volume":"104","author":"Advani","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2009.11.001_bib48","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1152\/japplphysiol.00599.2003","article-title":"Effect of nitric oxide on exercise-induced proteinuria in rats","volume":"95","author":"G\u00fcnd\u00fcz","year":"2003","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.ejca.2009.11.001_bib49","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2009.11.001_bib50","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","article-title":"The role of vascular endothelial growth factor (VEGF) in renal pathophysiology","volume":"65","author":"Schrijvers","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejca.2009.11.001_bib51","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature","volume":"290","author":"Kamba","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ejca.2009.11.001_bib52","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2009.11.001_bib53","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1111\/j.1523-1755.2005.00316.x","article-title":"Preeclampsia: a renal perspective","volume":"67","author":"Karumanchi","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejca.2009.11.001_bib54","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1097\/01.ASN.0000141038.28733.F2","article-title":"Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis","volume":"15","author":"Shimizu","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejca.2009.11.001_bib55","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1074\/jbc.C300012200","article-title":"Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria","volume":"278","author":"Sugimoto","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2009.11.001_bib56","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/sj.ki.5000439","article-title":"Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis","volume":"69","author":"Hara","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejca.2009.11.001_bib57","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/ndt\/gfl711","article-title":"Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia","volume":"22","author":"Garovic","year":"2007","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2009.11.001_bib58","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.2215\/CJN.03250807","article-title":"Slowing nephropathy progression: focus on proteinuria reduction","volume":"3","author":"Bakris","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejca.2009.11.001_bib59","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study","volume":"123","author":"Peterson","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2009.11.001_bib60","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejca.2009.11.001_bib61","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ajkd.2004.10.019","article-title":"Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy","volume":"45","author":"Atkins","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejca.2009.11.001_bib62","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/archinte.165.8.947","article-title":"The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American Study of Kidney Disease and hypertension","volume":"165","author":"Lea","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejca.2009.11.001_bib63","doi-asserted-by":"crossref","unstructured":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349:1857\u201363.","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"10.1016\/j.ejca.2009.11.001_bib64","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1111\/j.1600-6143.2007.01928.x","article-title":"Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence","volume":"7","author":"Hiremath","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ejca.2009.11.001_bib65","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1345\/aph.1H244","article-title":"Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension","volume":"40","author":"Dincer","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ejca.2009.11.001_bib66","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/j.1523-1755.2005.09303.x","article-title":"ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis","volume":"93","author":"Blanco","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejca.2009.11.001_bib67","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00003495-200363991-00003","article-title":"Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy","volume":"63","author":"Agabiti-Rosei","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.ejca.2009.11.001_bib68","doi-asserted-by":"crossref","unstructured":"K\/DOQI Clinical practice guidelines on hypertension and antihypertesnive agents in chronic kidney disease. Am J Kidney Dis 2004,43:S1\u2013290.","DOI":"10.1053\/j.ajkd.2004.03.003"},{"key":"10.1016\/j.ejca.2009.11.001_bib69","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the anti-proteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2009.11.001_bib70","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/sj.ki.5001655","article-title":"Direct effects of dexamethasone on human podocytes","volume":"70","author":"Xing","year":"2006","journal-title":"Kidney Int"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909008387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909008387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T06:43:39Z","timestamp":1634366619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804909008387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0959804909008387"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2009.11.001","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}